# CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

> **NCT05207722** · PHASE1,PHASE2 · TERMINATED · sponsor: **Celularity Incorporated** · enrollment: 1 (actual)

## Conditions studied

- Metastatic HER2 Positive Gastroesophageal Junction Cancer

## Interventions

- **BIOLOGICAL:** CYNK-101
- **DRUG:** Pembrolizumab
- **DRUG:** Trastuzumab
- **DRUG:** Recombinant Human Interleukin-2
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Mesna

## Key facts

- **NCT ID:** NCT05207722
- **Lead sponsor:** Celularity Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-14
- **Primary completion:** 2024-02-15
- **Final completion:** 2024-02-15
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** for business reasons
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05207722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05207722, "CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT05207722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*